- •Eleven patients with heterozygous FH under biweekly LDL apheresis were enrolled.
- •All the patients were switched from LDL apheresis to evolocumab injection therapy.
- •Evolocumab significantly reduces LDL-C by 62.5% compared with LDL apheresis.
- •No side effects were documented other than mild reduction in vitamin E serum levels.
Background and aims
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Monogenic hypercholesterolemia: new insights in pathogenesis and treatment.J. Clin. Invest. 2003; 111: 1795-1803
- Assessment of coronary atherosclerosis in patients with familial hypercholesterolemia by coronary computed tomography angiography.Am. J. Cardiol. 2015; 115: 724-729
- Efficacy and safety of coadministration of ezetimibe and simvastatin in adolescents with heterozygous familial hypercholesterolemia.J. Am. Coll. Cardiol. 2008; 52: 1421-1429
- Simvastatin with or without ezetimibe in familial hypercholesterolemia.N. Engl. J. Med. 2008; 358: 1431-1443
- Efficacy and safety of coadministration of rosuvastatin, ezetimibe, and colestimide in heterozygous familial hypercholesterolemia.Am. J. Cardiol. 2012; 109: 364-369
- Clinical applications of long-term LDL-apheresis on and beyond refractory hypercholesterolemia.Transfus. Apher. Sci. 2004; 30: 233-243
- The rebound of lipoproteins after LDL-apheresis. Kinetics and estimation of mean lipoprotein levels.Atherosclerosis. 2000; 152: 519-526
- A phase 3 study of evolocumab (AMG 145) in statin-treated Japanese patients at high cardiovascular risk.Am. J. Cardiol. 2016; 117: 40-47
- Evolocumab and clinical outcomes in patients with cardiovascular disease.N. Engl. J. Med. 2017; 376: 1713-1722
- Multicenter study to determine the diagnosis criteria of heterozygous familial hypercholesterolemia in Japan.J. Atheroscler. Thromb. 2012; 19: 1019-1026
- The rebound of lipoproteins after LDL-apheresis. Effects on chemical composition and LDL-oxidizability.Atherosclerosis. 1999; 147: 105-113
- Molecular genetic analysis of familial hypercholesterolemia: spectrum and regional difference of LDL receptor gene mutations in Japanese population.Atherosclerosis. 2002; 165: 335-342
- Impact of clinical signs and genetic diagnosis of familial hypercholesterolaemia on the prevalence of coronary artery disease in patients with severe hypercholesterolaemia.Eur. Heart J. 2017; (Epub ahead of print)https://doi.org/10.1093/eurheartj/ehx004
- Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolaemia Panel.Lancet Diabetes Endocrinol. 2016; 4: 850-861
- Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin/kexin type 9 through the low density lipoprotein receptor.J. Biol. Chem. 2015; 290: 11649-11662
- Variation in lipoprotein(a) concentrations among individuals with the same apolipoprotein (a) isoform is determined by the rate of lipoprotein(a) production.J. Clin. Invest. 1993; 91: 443-447
- Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial.Lancet. 2015; 385: 341-350
- Lifelong reduction of LDL-cholesterol related to a common variant in the LDL-receptor gene decreases the risk of coronary artery disease–a Mendelian Randomisation study.PLoS One. 2008; 3: e2986
- Genetic associations with valvular calcification and aortic stenosis.N. Engl. J. Med. 2013; 368: 503-512
- Effect of statins on noncholesterol sterol levels: implications for use of plant stanols and sterols.Am. J. Cardiol. 2005; 96: 40D-46D